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The Key Importance of Soy Isoflavone
Bioavailability to Understanding
Health Benefits
THERESA LARKIN,1,3 WILLIAM E. PRICE,1,2 and LEE ASTHEIMER1,3
Smart Food Centre,1 Department of Chemistry2 and Department of Biomedical Science,3 University of Wollongong,
NSW 2522, Australia
Research over the past two decades has provided significant epidemiological and other evidence for the health benefits of the
consumption of soy-based foods. A large number of dietary intervention studies have examined the effects of soy isoflavones on
risk factors for cardiovascular disease and hormone-dependent cancers. However, these report large variability in outcome
measures, very limited reproducibility between studies, and in some cases, controversy between the results of clinical trials
using dietary soy or soy protein and isoflavone supplementation. This highlights a major gap in our understanding of soy
isoflavone uptake, metabolism, distribution, and overall bioavailability. There are many potential factors that may influence
bioavailability and a better knowledge is necessary to rationalize the inconsistencies in the intervention and clinical studies.
This review focuses attention on our current state of knowledge in this area and highlights the importance of metabolism
of the parent soy isoflavones and the critical role of gut microbiota on the bioavailability of these compounds and their
metabolites.
Keywords Bioavailability, gut microbiota, soy isoflavones, equol, daidzein, genistein
INTRODUCTION
Among Asian populations with a high intake of soy, epi-
demiological evidence has demonstrated a lower incidence of
cardiovascular disease (Adlercreutz, 1990), hormone-dependent
cancers of the breast and prostate (Yu et al., 1991), colon can-
cer (Rose et al., 1986), menopausal symptoms (Clarkson, 2000),
and osteoporosis (Adlercreutz et al., 1992). These effects have
been extensively reviewed and will not be reiterated here (Wu
et al., 1998; Larkin et al., 2001; Murkies et al., 1998; Tham et
al., 1998; Setchell and Cassidy, 1999; Bingham et al., 1998;
Knight and Eden, 1996; Kurzer and Xu, 1997; Adlercreutz,
1995; Messina et al., 1994; Cassidy et al., 2000; Cassidy, 1996).
However, it should be noted that there is also a strong association
between dietary fat intake and cancers of the breast, prostate,
and colon (Rose et al., 1986). Although native Asian women
and men have the lowest rates of breast (Henderson and Bern-
stein, 1991) and prostate cancer (Yu et al., 1991; Ross et al.,
1995; Giovannucci, 1995), respectively, migration to Western
countries and the adoption of a more Western diet, increases the
incidence of these cancers amongst migrant Asians to an oc-
Address correspondence to William E. Price, School of Chemistry, Univer-
sity of Wollongong, NSW 2522, Australia. Tel: +61 2 42 213 509, Fax: +61 2
42 214 287. E-mail: wprice@uow.edu.au
currence similar to Western populations (Ziegler et al., 1993;
Whittemore et al., 1995). Similarly, while a cross-sectional study
in Japan revealed an inverse association between soy intake and
serum total cholesterol concentration (Nagata et al., 1998), an
increase in the incidence of cardiovascular disease is reported
for migrant Japanese (Kim et al., 1998). Thus diet, and in par-
ticular soy and its constituent isoflavones, have been implicated
as affording some protection against the development of these
hormone dependent cancers and cardiovascular disease.
In response to the epidemiological data, many soy dietary
intervention studies have been conducted in an attempt to eluci-
date the mechanisms involved. However, these report large vari-
ability in outcome measures and there is limited reproducibility
between studies (Lichtenstein, 1998). In 1999, the U.S. Food and
Drug Administration approved a health claim for the cholesterol-
lowering effects of soy protein, largely based on a meta-analysis
of 38 clinical trials that reported significant decreases in total
and LDL cholesterol and triglycerides with soy protein intake
compared with animal protein consumption (Anderson et al.,
1995). This prompted a burst of investigation to elucidate the
specific roles of isoflavones and soy protein in this hypocholes-
terolemic response; however, recent meta-analysis of the latter
research reported inconclusive results (Yeung and Yu, 2003). Di-
rect comparisons between studies are confounded by variations
in endogenous hormone levels (Potter et al., 1998) and baseline
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lipids of subjects (Gardner et al., 2001) as well as the dietary
sources of soy, isoflavone concentration (Steinberg et al., 2003),
intervention duration, and study design (Merz-Demlow et al.,
2000), all of which may impact on the results.
Isoflavones have both estrogenic activity and antioxidant
capacity, related to their structural similarity to 17β-estradiol
(Tham et al., 1998). These activities are relevant to the potential
roles of isoflavones in reducing cancer and cardiovascular dis-
ease risk, as free radicals, as well as high endogenous hormone
levels have been linked with the development of these condi-
tions (Zheng and Zhu, 1999). The isoflavones are able to bind
to estrogen receptors (ER) and elicit either a weak estrogenic
(agonistic) or anti-estrogenic (antagonistic) effect, depending
on the levels of endogenous estrogens present (Baghurst, 1997;
Wang and Kurzer, 1998) and the tissue and the ER subtype
(Kuiper et al., 1998; Setchell and Cassidy, 1999). Isoflavones
have a much higher affinity for ER-β than ER-α (Kuiper et al.,
1997; Nikov et al., 2000), thus tissues with a higher expres-
sion of ER-β might be more responsive to isoflavones (Ander-
son et al., 1999). The estrogen receptor activity of isoflavones
may play a major role in their effects against cancers of tis-
sues that express estrogen receptors (Cassidy, 1996) and in the
alleviation of menopausal symptoms (Wilcox et al., 1990; Per-
sky et al., 2002). The isoflavones also demonstrate good antioxi-
dant activity in various systems (Zheng and Zhu, 1999; Mitchell
et al., 1998) in both aqueous and lipophilic phases (Ruiz-Larrea
et al., 1997; Harper et al., 1999), attributed to a number of an-
tioxidant mechanisms (Mitchell et al., 1998; Arora et al., 1998;
Harper et al., 1999; Zheng and Zhu, 1999; Mitchell and Collins,
1999). The inhibition of lipid peroxidation, particularly of LDL,
by isoflavones may be an important mechanism by which they
positively influence lipid profiles.
For improvements in lipid levels, it appears that the soy pro-
tein matrix of isoflavones and intact soy protein may be more
beneficial than either component alone (Potter 1998; Steinberg
et al., 2003). Although the role of the individual soy components
in their influence on lipids has not been fully elucidated, soy pro-
tein may affect hepatic metabolism of cholesterol or lipoproteins
(Potter, 1998) or up-regulate LDL receptors (Anderson, 2003),
while the isoflavones may act via their estrogenic and antiox-
idant activities. These latter effects of isoflavones in reducing
lipid levels and LDL oxidation have been reported extensively
elsewhere and will not be re-iterated here (Vitolins et al., 2001).
Although less researched than the cardiovascular area, the estro-
genic, antioxidant, and anti-cancer activities of the isoflavones
have all been implicated in reducing the occurrence or devel-
opment of hormone-dependent cancers and are reported else-
where (Adlercreutz et al., 1995; Zheng and Zhu, 1999; Slavin
et al., 1997). In relation to soy-derived foods, the large inter-
individual variability in clinical and physiological effects may
depend greatly on isoflavone bioavailability and the soy matrix
in which they are contained.
To unravel some of these inconsistencies a much improved
understanding of soy isoflavone uptake, metabolism, tissue dis-
tribution, and overall bioavailability is needed. Bioavailability,
a term borrowed from pharmacology, has variable meanings in
a nutritional context. Here we use the term broadly to include a
full range of digestive and metabolic factors that influence the
amount and type of isoflavone compounds that reach the sys-
temic circulation. There are many factors that can influence
bioavailability and this review focuses attention on our current
state of knowledge of the area and highlights the importance of
metabolism of the parent soy isoflavones and the critical role of
gut microbiota on isoflavone bioavailability.
SOY–FOOD SOURCES AND ISOFLAVONE
COMPOSITIONS
To understand isoflavone bioavailability we need to have
a good understanding of the form in which isoflavone com-
pounds are found in foods, including those that have been
processed post-harvest. Isoflavones are not widely distributed
in plants, occurring almost exclusively in legumes (Coward
et al., 1993) with soybeans being the richest source of the
plant precursors of the endogenous isoflavones, daidzein (4′,7-
dihydroxyisoflavone), genistein (4′,5,7-trihydroxyisoflavone),
and glycitein (4′,7-dihydroxy-6-methoxyisoflavone) (Fig. 1).
Isoflavones are synthesized as part of the phenyl-propanoid path-
way, which has multiple branches common to legume and non-
legume plants and from which other flavonoids are also syn-
thesized (Parr and Bolwell, 2000; Yu et al., 2000; Hollman,
2001); however, their occurrence is limited because isoflavone
synthase, the enzyme required to convert their flavanone precur-
sors, is unique to legumes and only a few other species (Rolfe,
1988; Yu et al., 2000). This enzyme is developmentally and
tissue-specifically regulated and may be induced by environ-
mental stresses, particularly as the natural roles for isoflavones
are in plant-microbial interactions, including disease resistance
(Ebel, 1986; Yu et al., 2000). Formononetin and biochanin A,
the 4′-O-methoxylated isoflavone derivatives and precursors to
daidzein and genistein, respectively, occur in alfalfa and clover
seeds and sprouts, and in chick peas, garbanzo beans, black
bean seeds, and some pulses (Wang and Murphy, 1994a; Mur-
phy et al., 1999; Shoff et al., 1998; King et al., 1998; Franke et
al., 1994).
Soybeans are composed of the fleshy cotyledons, the part of
the seed that forms the first plant leaves; the hypocotyl, the part
of the axis of the plant embryo below the cotyledon and the hull,
the dry outer covering of the seed (Price and Fenwick, 1985).
The majority of isoflavones are concentrated in the hypocotyl,
where daidzein, glycitein, and their respective conjugates ac-
count for more than 95% of total isoflavones (Price and Fenwick,
1985). Glycitein and its three derivatives occur exclusively in the
hypocotyl (Wang and Murphy, 1994a), while genistein is found
both in the hypocotyl and cotyledon, predominating in the latter
(Erdman Jr. et al., 2004; Price and Fenwick, 1985).
The total isoflavone content of soybeans varies widely and
can be affected by crop year, soil conditions, local climate,
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Figure 1 Isoflavones structures.
genetics, and stage of maturity (Wang and Murphy, 1994a; Si-
monne et al., 2000; Franke et al., 1994). In addition, subsequent
processing and storage conditions will also affect isoflavone
yield (Wang et al., 1990; Eisen et al., 2003; Wang and Mur-
phy, 1994b). Amongst different varieties, total isoflavone con-
centrations have been reported to range from 0.1 to 5 mg to-
tal isoflavones (aglycones + conjugates) per gram of soybean
(Franke et al., 1995; Coward et al., 1993; Barnes et al., 1994;
Wang and Murphy, 1994a; Simonne et al., 2000). Genistein is
generally present at higher levels than daidzein and glycitein
in soybeans and most soy-derived foods (Setchell et al., 2001;
Franke et al., 1995). The variability in soy bean isoflavone com-
position is also reflected in other soy-derived foods; for example,
soy milk produced from soy beans from different regions of the
U.S., varies in total isoflavone content by up to approximately
70% (Murphy et al., 1999).
In traditional Asian diets, soy is consumed in many forms
including soybeans, soybean sprouts, toasted soy protein flours,
soy milk, tofu, and fermented soybean products such as miso,
tempeh, soybean paste, natto, and soy sauce (Coward et al.,
1993; Wang and Murphy, 1996). Soy consumption per indi-
vidual in most Asian countries is reported to be about 35
g per day (Coward et al., 1993); this equates to a daily in-
take of between 25 and 100 mg total isoflavones (aglycone
equivalents) (Messina, 1999; Coward et al., 1993; Setchell
et al., 2001) and between 8 and 12 g soy protein (Erdman
Jr. et al., 2004). In Western countries, soy intake is more
commonly in the form of soybean protein products includ-
ing flours, grits, isolates, concentrates, and textured soy pro-
teins (Wang and Murphy, 1996) with the average daily ex-
posure to isoflavones being less than 1 mg (aglycone equiva-
lents) (Adlercreutz et al., 1991; Messina et al., 1994; Wei et
al., 1995). Greater soy intake is reflected in plasma and urinary
isoflavone concentrations, which are higher in Japanese men
and women than Western populations (Adlercreutz et al., 1991)
and are also higher in vegetarians than omnivorous subjects
(Adlercreutz et al., 1993).
The isoflavones are present in four isomeric forms:
aglycones and three glucoside conjugates, the β-, acetyl-,
malonyl- and glucoside- conjugates (Wang and Murphy, 1994a;
Xu et al., 2000) (Fig. 2). The aglycones have no sugar residue
attached, whereas the glucoside conjugates have a sugar group
attached at the position 7 of the A ring. In whole soybeans,
the isoflavones occur mostly as 6′′-O-malonylglucoside conju-
gates, with the β-glucosides (daidzin and genistin) being the sec-
ond most abundant isoflavone derivatives (Coward et al., 1993).
In whole soybeans and other soy protein products, 97–98% of
the isoflavones are present as their esterified conjugates (Wang
and Murphy, 1994a); however, the glucoside composition of
soybean-derived foods varies, being determined by processing
conditions (Coward et al., 1998). Hot or acidic extraction proce-
dures cause decarboxylation of the 6′′-O-malonylglucoside con-
jugates in whole soybeans to produce the 6′′-O-acetylglucosides
conjugates, which can further undergo ester hydrolysis to form
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Figure 2 The four different isomers of daidzein in soy foods. Analogous
structures of genistein and glycitein are also present in soybeans.
the β-glucosides (Coward et al., 1993; Simonne et al., 2000;
Murphy et al., 1999; Barnes et al., 1994). While this does
not necessarily change the total amount of isoflavones ex-
tracted, the ratio of conjugated forms varies between soy foods
(Coward et al., 1998). Soy milk and tofu are produced from soy-
beans via hot aqueous extraction which results almost entirely
in the formation of β-glucosides (Barnes et al., 1994; Coward
et al., 1998; King and Bursill, 1998; Eisen et al., 2003). In fer-
mented soy products, unconjugated aglycones, resulting from
the action of the β-glucosidases of the fermentation organisms,
are the predominant chemical forms (Murphy et al., 1999; Cow-
ard et al., 1993; Fukutake et al., 1996). Compared with whole
soybeans, soy flour and soybean seeds generally contain slightly
less total isoflavone content (Franke et al., 1995; Franke et al.,
1994), while soy nuts, produced from dried late-harvest soy
beans, can have higher levels (Fukutake et al., 1996). Soy germ
products contain higher concentrations of daidzein and glycitein
than genistein due to the lower levels of genistein occurring in
the hypocotyl (Zhang et al., 1999).
Isoflavones are associated with the soluble components of
soybean, most probably soluble proteins (Wang and Murphy,
1996) and therefore, high protein soy ingredients contain similar
isoflavone concentrations compared with unprocessed soybeans
(Eisen et al., 2003). While ethanol extraction of soy flour to pro-
duce soy protein concentrate removes most of the isoflavones
(Coward et al., 1998, 1993), soy protein isolate produced from
hot water extraction of soy flour retains most of the isoflavones,
reflecting their strong protein binding and low aqueous solubil-
ity, and maintains the same pattern of conjugation as soybean,
(Coward et al., 1993). Soy protein concentrate prepared by aque-
ous extraction has a reported total isoflavone content (isoflavones
+ conjugates) of up to 2.7 mg/g, which is comparable to that
of soy flour and many Asian soybean products (Coward et al.,
1993), although the relative levels of protein-bound daidzein or
genistein can vary (Barnes et al., 1994; Franke et al., 1998).
Alcohol-extracted soy protein and soy isolates contain lesser
amounts of total isoflavones (Coward et al., 1993).
ISOFLAVONE BIOAVAILABILIITY
Isoflavone bioavailability is a measure of the amount of these
compounds that becomes available for tissue distribution where
they can exert physiological effects. Thus, an understanding of
bioavailability is important in assessing the potential health ben-
efits of isoflavones and may assist in the interpretation of the
high variability of results in clinical trials. The pharmacokinet-
ics of absorption, distribution, metabolism (bioconversion in the
gut and biotransformation in the liver), and elimination all con-
tribute to the bioavailability and subsequent effectiveness of the
isoflavones (Wiseman, 1999; Rowland et al., 2003). However,
most pharmacokinetic and bioavailability studies of isoflavones
and urinary concentrations of specific isoflavones and their
metabolites due to the ethical and practical difficulties of tissue
measurements. This does not provide a comprehensive under-
standing of bioavailability and distribution, as plasma isoflavone
concentrations simply represent the balance between absorption,
distribution, and urinary and biliary excretion (King, 1998). In
addition, the use of only plasma and urinary measurements of
isoflavones does not differentiate between the contributions of
the intestine, liver, or other organs in isoflavone metabolism (Liu
and Hu, 2002). The processes involved in isoflavone bioavail-
ability, summarized in Fig. 3 will be more thoroughly examined
in the following sections.
ISOFLAVONE ABSORPTION
After soy intake, the isoflavone glycosides are poorly ab-
sorbed in the small intestine because of their hydrophilicity and
large molecular weight (Xu et al., 1995; Liu and Hu, 2002).
Initial hydrolysis is thus necessary to release the free aglycones
which are rapidly absorbed via passive diffusion across the in-
testinal brush border (Scalbert and Williamson, 2000) with high
permeability (Liu and Hu, 2002). Glycosidase activity can oc-
cur in the food itself (via enzymes of endogenous origin or
added during processing), in the cells of the gastrointestinal
mucosa or the enzyme can be secreted by the colon microbiota
(Scalbert and Williamson, 2000). Isoflavones are detectable in
plasma as soon as 30 minutes after soy intake (King and Bursill,
1998) with an initial peak 1 hour post-meal (Franke et al., 1999;
Richelle et al., 2002). This early increase may be due to the
presence of a small proportion of aglycones available in the
soy meal (King and Bursill, 1998), but also suggests that hy-
drolysis and initial absorption occur readily in the duodenum
D
o
w
n
lo
ad
ed
 B
y:
 [
De
ak
in
 U
ni
ve
rs
it
y]
 A
t:
 0
3:
48
 1
1 
Se
pt
em
be
r 
20
09
542 T. LARKIN ET AL.
Figure 3 Diagram depicting the metabolism of isoflavones.
and proximal jejunum within the first hour of digestive pro-
cessing (Watanabe et al., 1998; Setchell et al., 2001; Rowland
et al., 2003).
A number of mammalian β-glucosidases have been identified
in the small intestine, including a broad specificity cytosolic β-
glucosidase enzyme and the membrane-bound lactase phlorizin
hydrolase (LPH) enzyme (Day et al., 1998). LPH is present
on the luminal side of the brush border in the small intestine
and can deglycosylate genistein-7-glucosidase and daidzein-7-
glucosidase within the gut lumen to release the more hydropho-
bic aglycones which can then diffuse into the epithelial cells
(Day et al., 2000). This activity suggests that the intestinal mu-
cosa plays an important role in the deglycosylation of isoflavones
(Day et al., 1998; Scalbert and Williamson, 2000) and confirms
the view that the isoflavone absorption begins in the proximal
small intestine (Xu et al., 1995) and occurs along its length
(Setchell et al., 2003b). The cytosolic β-glucosidase enzyme has
been identified in the small intestine, liver, and kidney of mam-
mals (Day et al., 1998), with the small intestine having a faster
rate of hydrolysis of the 7-glucosides of daidzein and genistein
than the liver (Day et al., 2000). However, intestinal hydrolysis of
isoflavones would require initial uptake of the glycoside form,
and although this has been demonstrated for other flavonoids
(Paganga and Rice-Evans, 1997), it has not been conclusively
shown for isoflavones (Setchell et al., 2002b). Isoflavone gly-
cosides that are not absorbed in the small intestine will pass
through to the colon, where bacterial β-glycosidases can hy-
drolyze them, removing the sugar moiety for energy conversion
(Parodi, 1999).
Plasma genistein is consistently reported as being higher than
that of daidzein after soy intake (King and Bursill, 1998). This
may simply reflect the generally higher levels of genistein and
its conjugates compared with daidzein and its conjugates in
most soy foods (Setchell et al., 2001), but has also been re-
ported when the intakes of daidzein and genistein are equiv-
alent (Setchell et al., 2003b). However, Xu, Wang, and oth-
ers (2000) reported similar plasma concentrations of daidzein
and genistein after intake of soy milk powder that contained
more genistein than daidzein. Experiments with pure com-
pounds and stable isotopically-labelled isoflavones suggest that
genistein is more bioavailable, with greater systemic exposure
than daidzein (Setchell et al., 2001; Setchell et al., 2003b). A
higher clearance rate of daidzein and its high volume of tis-
sue distribution also contribute to its consistently lower serum
concentrations compared with genistein (Setchell et al., 2003a).
In addition, LPH has shown a higher catalytic efficiency in
hydrolysis of genistein than of daidzein (Day et al., 2000),
a factor that may also contribute to the higher absorption of
genistein.
ISOFLAVONE METABOLISM
After initial absorption, the isoflavones undergo extensive
first-pass metabolism, which accounts for their low bioavail-
ability (Chen et al., 2003). During phase II biotransforma-
tion, the hydroxyl groups of the isoflavones provide sites for
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Figure 4 Glucuronide and sulphate conjugates of genistein. Analogous struc-
tures of daidzein are also present in the circulation.
glucuronidation and sulfation by glucuronosyl-transferases and
sulfotransferases in the liver (Xu et al., 1994) and/or intestine
(Setchell et al., 2001). The isoflavones undergo classical en-
terohepatic circulation and are conjugated in the liver, similar
to steroid metabolism (Winter and Bokkenheuser, 1987). The
glucuronide and sulphate conjugates (see Fig. 4) can be trans-
ported via the systemic circulation to tissues, from where they
will eventually be excreted via the kidneys, or they can be se-
creted in bile and returned to the intestine (Xu et al., 1995).
After deconjugation by intestinal bacteria, isoflavone aglycones
can be reabsorbed, then returned to the liver via the portal vein
for reconjugation and either further enterohepatic circulation or
renal excretion (Winter and Bokkenheuser, 1987).
Recent evidence suggests that the intestine and subsequent
enteric recycling may play a more significant role in isoflavone
metabolism and bioavailability than previously realized (Liu and
Hu, 2002; Chen et al., 2003). In rats, the portal vein contains pre-
dominantly 7-O-glucuronide isoflavones (Barnes et al., 1996),
suggesting that a primary site of glucuronidation is the intesti-
nal wall (Coldham and Sauer, 2000). This was confirmed by
evidence that in rats MRP (multi-drug resistance-related pro-
tein) conjugated and the small intestine efficiently secreted glu-
curonidated isoflavones into the intestinal lumen (Liu and Hu,
2002). Chen, Lin, and co-authors (2003) reported that in vitro,
significant amounts of genistein were glucuronidated and sul-
phated by intestinal cells and these products were then excreted
into both the apical and basolateral sides of the enterocyte.
These authors further suggested that upper intestinal isoflavone
metabolism could surpass that of the liver. Thus, the intestinal
conjugation of isoflavones, their secretion back into the intestinal
lumen and, further reabsorption and reconjugation constitutes
enteric recycling (Liu and Hu, 2002; Chen et al., 2003), which,
in combination with enterohepatic recycling, significantly pro-
longs systemic exposure to isoflavones (Turner et al., 2003).
In circulation, the aglycones represent only a small frac-
tion of the total plasma isoflavones (Shelnutt et al., 2002). The
glucuronides are the predominant metabolites of isoflavones
(Zhang et al., 2003; Spencer et al., 1999), followed by the sul-
phated conjugates (Adlercreutz et al., 1993) with other con-
jugates including sufloglucuronides (Adlercreutz et al., 1993).
In addition, isoflavones also bind to plasma proteins (Cold-
ham and Sauer, 2000). After soy intake, the percentage of
total plasma daidzein present as glucuronides (Zhang et al.,
2003) and sulphates (Shelnutt et al., 2002) is greater than that
of genistein. For estrogens, the sulphate conjugates are excreted
slowly compared with the glucuronide conjugates, and can serve
as a source of biologically active estrogens when hydrolyzed
in target tissues (Adlercreutz et al., 1987). However, the sul-
phate conjugates of both daidzein and genistein are cleared
faster than the glucuronides (Shelnutt et al., 2002). In addi-
tion, while the concentration of daidzein sulphate in plasma is
much higher than genistein sulphate, it is cleared faster, but these
two compounds show similar urinary recovery (Shelnutt et al.,
2002); this may reflect a greater tissue distribution of daidzein
sulphate.
Maximal plasma concentrations of daidzein and genistein
are generally reached between 6 and 8 hours after soy intake
in humans (Setchell et al., 2003b; Setchell and Cassidy, 1999;
King and Bursill, 1998; Setchell et al., 2003a; Xu et al., 1994;
Xu et al., 1995); daidzein often reaches its peak concentration
later but has a faster plasma disappearance rate than genistein
(Shelnutt et al., 2002). The half-lives of plasma elimination are
dependent on the conjugate; these are 3–9 hours for daidzein
and 8–11 hours for genistein after intake of soy foods or pure
isoflavone glycosides (Watanabe et al., 1998; Shelnutt et al.,
2002; Setchell et al., 2003b), but 9 and 7 hours for pure daidzein
and genistein aglycone administration respectively (Setchell
et al., 2001).
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Whether returned to the intestinal lumen via excretion in bile
or by enterocytes, the isoflavone conjugates are deconjugated
by enzymes in the intestinal wall (β-glucuronidases) or bac-
terial enzymes (β-glucuronidases and sulfatases) (Winter and
Bokkenheuser, 1987; Chen et al., 2003). Aglycones that are not
reabsorbed will reach the colon, along with any conjugates from
liver or intestinal biotransformation that are not deconjugated
(Liu and Hu, 2002) and the fraction of the isoflavone that is
neither hydrolyzed nor absorbed in the small intestine initially
(Decroos et al., 2005). Between 30 and 50% of estrogen metabo-
lites are excreted in bile and about 80% of biliary conjugates are
reabsorbed (Adlercreutz et al., 1987) with less than 10% excreted
in the faeces (Thompson, 1994). Similarly for isoflavones, mea-
surement of intact isoflavones has accounted for only between
15 and 30% of the ingested dose and fecal excretion is also low
(Xu et al., 1995). Thus, the majority of unaccounted isoflavone
dose must be metabolized in the intestine (Rowland et al., 2003)
and/or more extensive metabolism must take place in the tissues,
liver, and circulation (Spencer et al., 1999).
In the colon, secondary metabolites are more easily absorbed
(Chen et al., 2003) and colonic microbiota further degrade the
isoflavones to simpler compounds which may involve splitting
of the heterocyclic oxygen containing ring (Hollman, 2001;
Scalbert and Williamson, 2000). Both daidzein and genistein
can be further metabolized to secondary metabolites via the in-
termediates dihydrodaidzein and dihydrogenistein, respectively.
Daidzein can be metabolized by reduction to equol or ring cleav-
age to O-desmethylangolensin (ODMA) and genistein to p-
ethyl phenol or 6′-hydroxy-O-desmethylangolensin (6′ODMA),
although, of these secondary metabolites, only equol is bio-
logically active (Hutchins et al., 1995; Setchell et al., 2002a).
Metabolism to equol and ODMA appears to be inversely related,
suggesting two alternative pathways for daidzein metabolism
(Kelly et al., 1995). In addition, a number of other minor
metabolites of both daidzein and genistein have been identi-
fied in plasma, urine, and faeces (Kelly et al., 1993; Heinonen
et al., 1999; Chang and Nair, 1995; Joannou et al., 1995). The
higher molecular weight and lower water solubility of genis-
tein may promote excretion of genistein conjugates in bile and
provide more opportunity for bacterial degradation (Xu et al.,
1994), whereas daidzein appears to be less subjected to bac-
terial metabolism in vivo. Thus, daidzein is more likely to be
absorbed and therefore potentially more bioavailable (Decroos
et al., 2005). It has also been suggested that the carbonyl moiety
of genistein is protected by hydrogen bonding to the adjacent
hydroxyl group, thus rendering it less reactive in contrast to the
carbonyl moiety of daidzein that may be readily metabolized by
reduction and dehydration to equol (Coldham et al., 2002).
DISTRIBUTION, ELIMINATION AND RECOVERY
OF ISOFLAVONES
Isoflavones have been quantified in plasma, urine, bile, and
feces, as well as in human saliva, breast aspirate, and prostatic
fluid (Morton et al., 1997). They have also been shown to ac-
cumulate in breast tissue and milk (Franke et al., 1998; Franke
and Custer, 1996; Pumford et al., 2002; Maubach et al., 2003)
and to cross the blood brain barrier and placenta (Setchell
and Cassidy, 1999; Adlercreutz et al., 1999). In men from
soy-consuming countries, levels of isoflavones are higher in
prostatic fluid than those of Western populations and concen-
trated approximately 2-fold relative to plasma (Morton et al.,
1997). Setchell and co-authors (2001) have estimated a large
volume of distribution for the isoflavone aglycones and sec-
ondary metabolites indicating that they have the potential to
modulate physiological actions at a range of tissues. Busby and
colleagues (2004) determined that the volume of distribution
of free plasma daidzein and genistein was nearly twice that of
their respective conjugates. The aglycones are also cleared from
the plasma much more rapidly than conjugated isoflavones, sug-
gesting that free isoflavones enter and perhaps are sequestered in
tissues.
Isoflavones are excreted in urine almost exclusively as acidic
conjugates, mainly glucuronides, with lesser amounts of sul-
phates and sulphoglucuronides (Adlercreutz et al., 1993). After
soy intake, urinary excretion of daidzein and genistein is typ-
ically highest 7–8 hours post-meal (Watanabe et al., 1998; Lu
et al., 1995). King and Bursill (1998) reported that mean ex-
cretion rates for genistein and daidzein increased progressively
reaching a peak 6–12 hours after the meal and Watanabe and
others (1998) found that a plateau was reached 8–12 hours af-
ter intake. The majority of the urinary excretion of daidzein
and genistein occurs within the first 24 hours after soy inges-
tion (Lu et al., 1995; Setchell et al., 2003b). Although King
and Bursill (1998) suggested a constant elimination rate be-
tween 11 and 35 hours after a meal, Watanabe and colleagues
(1998) showed that during 48 hours post soy intake, sub-
jects characteristically showed two or three peaks of daidzein
and genistein excretion, and attributed this to enterohepatic
circulation.
In contrast to the higher plasma concentrations of genistein
compared with daidzein, most studies report greater urinary ex-
cretion of daidzein (Xu et al., 1994; Franke et al., 1999). In ad-
dition, a higher proportion of daidzein occurs in urine in the un-
conjugated form (Adlercreutz et al., 1993). It has been suggested
that the lower molecular weight (254 vs. 270) and greater water
solubility of daidzein could account for its higher urinary excre-
tion (Xu et al., 1994), while the lower hydrophilicity of genis-
tein may promote its excretion in bile (King and Bursill, 1998).
The proportional urinary recovery of isoflavones, relative to the
amount ingested, is generally quite low, reported to be between
10 and 50% (Cassidy et al., 2000; Hendrich et al., 1998), pos-
sibly indicating significant colonic bacterial degradation and/or
metabolism to other unidentified compounds (Xu et al., 1994;
Lampe et al., 1998). Hendrich and co-authors (1998) suggested
that biliary excretion is likely to be the main limiting factor with
respect to the percentage of isoflavones that are systemically
available after intake. In addition, cytochrome p450 enzymes
appear to play an important role in the oxidative metabolism
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of the soy isoflavones and might explain their low recoveries
(Kulling et al., 2000). Total fecal excretion of isoflavones is typ-
ically less than 5% (Xu et al., 1994; Xu et al., 1995; Watanabe
et al., 1998), predominantly in the unconjugated form with less
than 10% being conjugated (Adlercreutz et al., 1995).
PRODUCTION OF EQUOL
The conversion of daidzein to equol may be physiologically
important as equol has significantly greater antioxidant activity
(Mitchell et al., 1998; Arora et al., 1998; Wiseman and O’Reilly,
1997; Vedavanam et al., 1999) and estrogenic activity (approx-
imately 100-fold higher) on binding to the ER (Sathyamoorthy
and Wang, 1997) compared with daidzein. A case-control study
found a substantial reduction in breast cancer risk among women
with high excretion of isoflavones, with those excreting equol
having the greatest reduction (Ingram et al., 1997). Similarly,
Akaza and co-authors (2002) reported that the percentage of
male equol-producers in a case-control study was significantly
lower among patients with prostate cancer compared with con-
trols. Further, the greatest increases in the menstrual cycle fol-
licular phase, a change associated with lower breast cancer
risk, were found in two subjects who also had the highest uri-
nary equol excretion in a soy supplementation study (Cassidy
et al., 1994). However, as highlighted in a recent review pa-
per (Atkinson et al., 2005), most studies that have associated
equol production with health benefits have done so with only
weak, if any, statistical significance. Furthermore, the review
highlighted many studies that report no differences in health
effects or biomarkers for pathologies based on an individual’s
ability to produce equol. It is clear that more research needs to
be conducted in this area as currently the evidence is lacking and
inconclusive.
Equol is exclusively produced by intestinal bacteria
(Decroos et al., 2005), but not all people can metabolize
daidzein to equol. It is consistently reported that among subjects
of Caucasian background, between 30 and 40% of individuals
excrete equol after consuming soy products (Lampe et al., 2001;
Slavin et al., 1998; Lampe et al., 1998); however, this propor-
tion is much higher in Asian countries of between 45 and 60%
(2002). The presence of equol in urine or plasma has been used
by researchers to classify subjects with analysis of outcomes
in relation to equol-producing ability (Rowland, 1999; Kelly
et al., 1995; Lampe et al., 1998; Karr et al., 1997; Setchell et al.,
2002a).
Equol is unique in having a chiral center due to the absence
of a double bond in the heterocyclic ring, resulting in two dis-
tinct optically active isomers. The naturally occurring enan-
tiomer from endogenous conversion of daidzein is S(−)equol
(Muthyala et al., 2004). The R and S isomers differ conforma-
tionally, with the beings form being more non-planar (Setchell
et al., 2002a), suggesting a higher affinity of this isomer for es-
trogen receptors (Barnes and Peterson, 1995). It has recently
been confirmed that S(−)equol has a high binding affinity and
strong preference for ER-β, whereas R(+)equol has lower affin-
ity and a preference for ER-α (Muthyala et al., 2004). The
non-planar structure of S(−)equol also gives it greater flexi-
bility for conformational changes, which may allow it to pen-
etrate into cell membranes with greater ease than the other
more rigid isoflavones (Arora et al., 1998). This is impor-
tant in terms of the use of isoflavone supplements, since con-
suming a racemic mixture of equol from a synthetic source
would not be expected to have the same physiological ef-
fects as the entantiomer product of endogenous metabolism of
daidzein.
The pharmacokinetics of equol are similar to the other
isoflavones; however, equol has a slower plasma clearance
(Setchell et al., 2002a; Lampe et al., 2001) and a longer half-
life (Kelly et al., 1995) than daidzein, with maximal plasma
levels generally reached between 24 hours and 3 days post-
intake (Setchell et al., 2001; Kelly et al., 1995). Metabolism
of daidzein to equol is time-dependent (Setchell et al., 2003a)
with a lag time in its appearance of at least 6–8 hours after in-
take of a bolus dose, consistent with its colonic origin (Setchell
et al., 2001; Setchell et al., 2003b). Equol is readily absorbed
from the gastrointestinal tract, more efficiently through the colon
wall compared with daidzein (Decroos et al., 2005), and con-
jugated to glucuronic acid in the liver (Axelson et al., 1982).
Hepatic metabolism may be more important for compounds like
equol, that are mainly absorbed from the large intestine (Chen
et al., 2003) and this may contribute to longer pharmacokinet-
ics. The formation of equol may be dependent on initial levels
of daidzein (Tsangalis et al., 2002) and equol bioavailability is
reportedly greater after ingestion of daidzein glucoside rather
than the aglycone, possibly due to the longer transit time of
the former (Zubik and Meydani, 2003). Once formed, equol
appears to be metabolically stable, undergoing no further bio-
transformation, other than phase II metabolism (Setchell et al.,
2002a); however, it has been recently suggested that equol is
further metabolized, possibly in the liver, leading to catecholic
structures of either ring A or B (Adlercreutz et al., 2004). Al-
though glycitein metabolism is poorly understood, recent liter-
ature implies that equol-like metabolites may be produced from
glycitein. Heinonen and co-authors (2003) identified glycitein
metabolites in human urine after soy consumption and found
significant amounts of 4′,6,7-trihydroxyisoflavone, a compound
differing from equol only in the presence of an extra hydroxyl
group.
Equol also remains elevated in the urine for longer af-
ter a soy challenge compared with daidzein and genistein
(Lampe et al., 2001), with maximum urinary excretion reported
between 24 and 72 hours or more after intake (Kelly et al., 1995;
Kelly et al., 1993; Axelson et al., 1982; Xu et al., 1994). It is ex-
creted in urine almost exclusively as the monoglucuronide con-
jugate (Axelson et al., 1982). Watanabe and co-authors (1998)
calculated the percent metabolic conversions of daidzein to O-
DMA and equol as 4 and 7%, respectively and reported that the
fecal excretion of equol was much higher, 5–6 days compared
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with 4 days after intake, suggesting that much of the fecal equol
represents biliary excretion.
ROLE OF THE GUT MICROBIOTA IN ISOFLAVONE
BIOAVAILABILITY
The essential role of the gut microbiota in isoflavone absorp-
tion and metabolism has been demonstrated through the use of
antibiotics which dramatically decrease plasma isoflavone con-
centrations and urinary excretion of the bacterial metabolites
(Winter and Bokkenheuser, 1987; Rowland, 1999; Adlercreutz,
1998). Additionally, studies using “germ-free” rats show the
absence of isoflavone absorption, which is revived after inocu-
lation with human gut flora (Bowey et al., 2003). The enzymes
most pertinent to isoflavone uptake are the β-glucosidases,
necessary for glycoside hydrolysis and aglycone absorption,
as this initial hydrolysis to the aglycone appears to be the
rate-limiting step in isoflavone absorption (Izumi et al., 2000;
Setchell et al., 2001; Steer et al., 2003). In the gastrointestinal
tract, β-glucosidase enzymes are produced by several groups
of bacteria including Lactobacilli, Bacteroides and Bifidobac-
teria (Steer et al., 2003; Xu et al., 1995), of which the latter
two comprise the majority of microorganisms in the human
gastrointestinal tract (Friend and Chang, 1984). Following ini-
tial absorption, endogenous β-glucuronidases and sulfatases
are required for reabsorption of the hepatic conjugates and
biliary excretion (Xu et al., 2000). The relative contribution
of intestinal and bacterial enzymes has not been established;
however, both appear to play an important role in isoflavone
bioavailability.
The extent to which compounds are metabolized by gut bac-
teria depends on a range of factors, notably, the region of the
gut from which the compound is absorbed, the distribution and
type of bacteria and the availability of the necessary enzyme
(Hawksworth et al., 1971). The microbiota of the large intestine
is acquired after birth, with a pattern resembling adult flora es-
tablished after weaning (Isolauri, 2001; Salminen et al., 1998).
The species composition that develops is largely controlled by
diet (Salminen et al., 1998), which especially affects gut mi-
crobial enzyme activities during the transition to a more diver-
sified diet, between 6 and 12 months (Mykkanen et al., 1997).
Bacterial numbers and composition vary considerably along the
human gastrointestinal tract, with numbers increasing along the
length of the small intestine to approximately 108 per mL of
contents at the ileocecal region (Salminen et al., 1998). The
large intestine usually contains more than 400 species of bac-
teria (Parodi, 1999), typically 1012 bacteria per gram contents
(Salminen et al., 1998; Gibson, 1998). In the proximal small in-
testine (duodenum and jejunum), where absorption is at its peak,
the microbiota is dominated by species of Streptococcus, Lac-
tobacillus and Bifidobacterium, while in the distal small intes-
tine (ileum) and colon, Bacteroides and Bifidobacterium species
dominate (Parodi, 1999; Turner et al., 2003). Of the gut micro-
biota, enterococci (found in high levels in the colon) have the
highest β-glucosidase activity, followed by Lactobacilli, Bac-
teroides and Bifidobacteria. In vitro, Bifidobacteria can me-
tabolize the isoflavone glycosides and further metabolism of
daidzein to equol is correlated with its β-glucosidase activity
(Tsangalis et al., 2002).
Recently, much research has been directed towards the elu-
cidation of the bacteria responsible for the production of equol
from daidzein. It appears that more than one bacterial species
is involved in the metabolism of daidzein to equol (Hur et
al., 2000; Decroos et al., 2005) with strains of bifidobac-
teria (Tsangalis et al., 2002), streptococci, ruminococci, bac-
teroides (Ueno and Uchiyama, 2001), enterococci, and lacto-
bacilli (Decroos et al., 2005) as well as Escherichia coli (Hur
et al., 2000), have all been identified as having this capability.
Thus, the presence or absence of equol will depend on an individ-
ual’s microbiota composition and bacterial enzyme expression
(Turner et al., 2003). Urinary excretion of equol seems to be
inversely related to that of daidzein and ODMA (Kelly et al.,
1993; Kelly et al., 1995; Slavin et al., 1998; Lampe et al., 2001),
suggesting that daidzein is preferentially metabolized to either
ODMA or equol, depending on gut microbiota and/or other in-
herent characteristics. Decroos and co-authors (2005) reported
that equol and O-DMA are indeed formed by different bacteria,
but that these species can co-exist. Thus, equol-excretor status
may be a marker of a particular colonic microbial profile (Lampe
et al., 2001) although it is not known whether this can be mod-
ulated by diet. The relationship between an individual’s ability
to produce equol and their inherent gut microbial balance is not
known but may have significant impact in relation to potential
health benefits of soy consumption (Atkinson et al., 2005).
FACTORS AFFECTING ISOFLAVONE
BIOAVAILABILITY
A number of factors can influence the absorption of food
components, including dietary habits, the food matrix, intesti-
nal fermentation, and transit time (Zubik and Meydani, 2003).
In isoflavone bioavailability studies, the soy food used and its
isoflavone composition are important determinants of the re-
sulting isoflavone pharmacokinetics and potential physiological
effects. The influence of diet is important due to interactions
between dietary components and because diet has a strong ef-
fect on the composition of the gut microbiota, which in turn
plays a crucial role in isoflavone bioavailability. Inherent and
genetic characteristics which determine pathways of absorption
and metabolism will also contribute to variability in isoflavone
bioavailability. A better understanding of these differences will
assist in the interpretation of outcomes of dietary studies. In-
formation regarding genetic and inherent influences as opposed
to dietary-induced effects on isoflavone bioavailability and any
consequent health effects is lacking and would benefit from fur-
ther investigation.
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EFFECTS OF ISOFLAVONE CONJUGATION
ON BIOAVAILABILITY
The relative proportions of different isoflavone conjugates
in soy may have an effect on resulting bioavailability. It is not
known what effects 6′′-O-substitution has on the susceptibility of
the isoflavone conjugates to intestinal hydrolysis and absorption;
however, differences in bioavailability and metabolism depen-
dent on the nature of their chemical form would be anticipated
(Barnes et al., 1994). There are differences in the location of
absorption of these conjugates, as the aglycones are absorbed
readily from the upper small intestine, the β-glucoside con-
jugates from the distal small intestine after hydrolysis to the
aglycone, and the malonylglucoside and acetylglucoside con-
jugates from the large intestine after hydrolysis (Coward et al.,
1998). This could affect the subsequent bioavailability of the
aglycones as absorption efficiency and the distribution of conju-
gating enzymes differs between different areas of the gastroin-
testinal tract (Liu and Hu, 2002). More specifically, the propor-
tions of daidzein, genistein, and glycitein, will also greatly affect
the resulting isoflavone bioavailability and overall physiologi-
cal effects, due to their different chemical structures and in vivo
properties.
Most soy-containing foods consumed in Western diets are
made from soy protein which contains glycosidic isoflavones,
as opposed to fermented soy products in which aglycones pre-
dominate (Setchell et al., 2001). Although there are differences
in the kinetics of plasma absorption and excretion after con-
sumption of β-glucosides compared with aglycones, there does
not appear to be an overall difference in systemic bioavailabil-
ity using a measure of area under the curve (Steer et al., 2003).
The aglycones are absorbed faster and with greater maximum
concentration; however, plasma levels do not remain elevated
for as long (Izumi et al., 2000), while the glycoside conjugates
take longer both to reach maximum plasma concentration and
to be cleared from the plasma (Setchell et al., 2001; Steer et
al., 2003). These differences in pharmacokinetics would pre-
sumably affect tissue exposure and overall bioavailability; how-
ever, the nature of these effects has not yet been established.
In addition, the conjugation may also determine the extent to
which the isoflavones are metabolized to secondary metabolites
and Zubik and Meydani (2003) suggested that the longer transit
time for glucosides may provide more opportunity for bacterial
metabolism (Zubik and Meydani, 2003). The food matrix will
also influence subsequent bioavailability, with isoflavones from
supplements likely to be absorbed at a faster rate than those
ingested in a food matrix (Richelle et al., 2002).
LEVEL AND DURATION OF ISOFLAVONE INTAKE
In a dose-dependent analysis using pure isoflavone supple-
ments, Setchell and co-authors (2003a) reported no effect of
isoflavone dose on the time to maximum plasma concentration,
but there was a decreased fractional absorption when the dose
was doubled from 0.4 to 0.8 mg/kg body weight, indicating that
a plateau was reached and that absorption may be rate-limited.
Similarly, intake of soy nuts at three different amounts resulted
in similar half-lives, clearance, and volume of distribution, inde-
pendent of dose (Setchell et al., 2003b). Although Hendrich and
others (1998) reported that human bioavailability of isoflavones
is linearly related to dose within a broad range, it is possible that
non dose-dependent plasma kinetics at higher intakes may result
in saturable plasma levels (Setchell and Cassidy, 1999; Setchell
et al., 2001). However, once absorbed, dietary polyphenols in-
cluding isoflavones are not expected to saturate metabolic path-
ways, but dose will determine the primary site of metabolism
(Scalbert and Williamson, 2000). Large doses will be metabo-
lized primarily in the liver, while smaller doses may be metabo-
lized predominantly by intestinal mucosa with the liver playing
a secondary role (Scalbert and Williamson, 2000). Apart from
the effects of first-pass metabolism reducing overall bioavail-
ability, these two sites differ in terms of the types of reactions
that predominate, which may affect metabolite production. In the
liver, oxidative metabolism predominates, whereas the gut is ac-
tive in reductive reactions (Rowland, 1986) and the metabolism
of daidzein to equol occurs almost exclusively via intestinal
metabolism (Rowland, 1999). It is not known how subsequent
bioavailability and tissue distribution is affected by the location
of isoflavone metabolism.
Long-term soy intake may also affect isoflavone bioavail-
ability if enzymes important for isoflavone bioavailability are
induced by prior exposure. Bacterial β-glucuronidase has been
demonstrated to be inducible by glucuronide conjugates (Silvi
et al., 1999) and this may be similar for other enzymes. Four
weeks of soy milk ingestion increased the absorption half-lives
of daidzein and equol as well as the proportion of free unconju-
gated isoflavones (Lu et al., 1995), which may result in greater
isoflavone bioavailability. Hendrich and colleagues (1998) re-
ported that more frequent doses prolong plasma clearance time.
However, there does not appear to be an effect of long-term
intake (up to 10 weeks) of soy foods on absolute plasma con-
centrations (Wiseman et al., 2004).
EFFECTS OF GENETICS AND DIET ON GUT
MICROBIOTA
The species composition of gut microbiota and to-
tal activity of enzymes vary widely between individuals
(Salminen et al., 1998; Day et al., 1998) and host genetic
polymorphism has been demonstrated for a number of en-
zymes (Scalbert and Williamson, 2000). The expression of β-
glucuronidases in human cells is often regulated during devel-
opment (Scalbert and Williamson, 2000). LPH, which has been
implicated as having a major role in intestinal absorption of
isoflavone aglycones, is also primarily responsible for hydroly-
sis of lactose and deficiency of this enzyme causes lactose intol-
erance (Day et al., 1998). This condition affects approximately
5% of Europeans and 90% of Africans and Asians in adulthood
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(Scalbert and Williamson, 2000). For those individuals who are
deficient in LPH, isoflavone absorption in the small intestine may
be reduced which would result in more isoflavones reaching the
colon for microbial metabolism (Day et al., 2000), including the
conversion of daidzein to equol. Furthermore, Thadepalli and
co-authors (1979) reported differences between the gastroin-
testinal microbiota of North Americans and Western Europeans
compared with South Indian and Guatemalan individuals.
Human intestinal microbiota composition is relatively stable
(Lampe et al., 1998) and differences in normal dietary patterns
do not appear to influence the composition of the intestinal mi-
crobiota extensively. However, diet and antibiotics can substan-
tially modify the metabolic activity of bacteria including that
of β-glucosidases and β-glucuronidases (Parodi, 1999; Persky
et al., 2002) and enterohepatic circulation of nutrients (Goldin
et al., 1982; Gorbach and Goldin, 1992). For instance, vegans
have lower fecal β-glucuronidase activity (Parodi, 1999) and
transition to a vegan diet in adults alters fecal bacterial enzyme
activities (Mykkanen et al., 1997). Dietary induced changes in
gut microbiota and enterohepatic circulation may subsequently
affect isoflavone bioavailability. In addition, dietary substrates
such as fiber can also modulate intestinal and fecal characteris-
tics including transit time, bulk, and water content (Parodi, 1999)
and conversely, these fecal characteristics can influence sub-
strate availability, redox potential in the colon (Gibson, 1998),
and accessibility of bacteria for dietary substrates (Parodi, 1999).
The principal substrates for colonic bacterial growth are di-
etary carbohydrates that have not been digested in the upper
intestinal tract (Gibson, 1998; Yue and Waring, 1995). Most gen-
era of the large intestinal microbiota are saccharolytic and obtain
energy by fermentation of such dietary carbohydrates, including
non-starch polysaccharides and resistant starch (Parodi, 1999).
Recently, much research has been focused on modulation of gut
microbiota from either oral intake of probiotic bacteria or inges-
tion of a prebiotic, which can induce the activities of specific
endogenous probiotic gut microbiota, with expected subsequent
effects on isoflavone bioavailability.
Prebiotic effects in the gastrointestinal tract may be particu-
larly relevant to equol production as the metabolism of daidzein
to equol relies exclusively on gut microbiota (Decroos et al.,
2005). Although Kelly and co-workers (1993) suggested that
genetics may play a role in the ability to metabolize daidzein
to equol, gut microbiota may be a co-determinant. If this is the
case, it may be possible to alter bacterial composition via dietary
intervention in a manner favorable to equol production. An in-
dividual’s ability to produce equol has been associated with low
dietary fat intake (Lampe et al., 2001) and with a greater intake of
carbohydrate (Lampe et al., 2001), non-starch polysaccharides
(Rowland, 1999) and dietary fiber (Lampe et al., 1998). In par-
ticular, the type and amount of carbohydrate available to intesti-
nal microbiota may be important for equol-producing capacity
(Rowland, 1999; Lampe et al., 2001) and experiments using an
in vitro colonic fermentation system found that a high carbohy-
drate environment increased fermentation and the rate of con-
version of daidzein to equol (Setchell and Cassidy, 1999). Thus,
increased intake of carbohydrate, either acutely or via habitual
diet, may also increase equol production in vivo. In vivo effects
on the metabolism of daidzein to equol could influence the po-
tential health protective effects of soybean isoflavones if indeed
equol has greater impacts on physiological function (Wiseman,
1999). It still remains to be established whether equol-producing
ability is indicative of a microbial balance predisposed to health
effects or whether the microbiota can be modified by diet to
enhance isoflavone bioavailability and/or equol production and
any consequent health effects (Atkinson et al., 2005). However,
the latter has not been conclusively established and again high-
lights the need for further research for more conclusive results
related to soy isoflavones, isoflavone bioavailability, and human
health outcome measures.
CONCLUSIONS
The substantial evidence supporting the potential for bene-
ficial effects of soy consumption has led to much wider use of
traditional soy products in Western societies and to the develop-
ment of new isoflavone and soy-enriched foods and supplements.
However, the high level of variability in clinical outcome mea-
sures means that it is very difficult to unravel the various effects
and to shed light upon the mechanisms by which isoflavones may
act and influence health outcomes. This high level of variability
is in large part due to the inter-individual variation in the bioavail-
ability of the isoflavones. This review has focused on the central
importance of understanding the factors influencing isoflavone
bioavailability. The process by which the isoflavones are dis-
tributed to tissues and hence exert their physiological effects has
been shown to be a complex one with many components. These
include uptake and absorption, first pass metabolism, and then
enterohepatic circulation via conjugation in the liver. The role of
biotransformation to various conjugates together with the level
and duration of isoflavone consumption have been shown to be
of importance. Furthermore, the effects of habitual diet on gut
microbiota may be one of the most important factors affecting
isoflavone bioavailability and thus, modulation of physiological
effects. One of the attractive features of a focus on background
diet is that it is an easily modified condition. In addition, the role
of gut microbiota may be particularly important in the produc-
tion of the daidzein metabolite equol, which may confer more
health benefits than its precursor. Much more research needs to
be carried out in this area, in order to understand how soy can
have health benefits in the broader population.
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